Printed From BioPortfolio.com
FDA approves Phase Ib/IIa study of GNS561 for treatment of liver cancer
07:00 EST 8 Dec 2017 | EPM Magazine
Genoscience Pharma has announced that initiation of a Phase Ib/IIa study of its most advanced compound, GNS561, for the treatment of patients with advanced hepatocarcinoma (HCC), has received approval from the US Food and Drug Administration (FDA).
Original Article: FDA approves Phase Ib/IIa study of GNS561 for treatment of liver cancer
